Creative Planning
MAIA icon

Creative Planning’s MAIA Biotechnology MAIA Stock Holding History

Creative Planning’s Portfolio MAIA Stock Details MAIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-28,602
Closed -$40K – 4367
2026
Q1 		$40K Sell
28,602
-220
-0.8% -$406 ﹤0.01% 4005
2025
Q4 		$44.1K Buy
+28,822
New +$37.6K ﹤0.01% 3814

Other funds holding MAIA

SCM
Solas Capital Management Darien, Connecticut $187M AUM 12.91% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
CWM
Centric Wealth Management Chicago, Illinois $643M AUM 21% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Creative Planning's MAIA Position: Q2 2026 in Review

Creative Planning sold out of MAIA Biotechnology (MAIA) in Q2 2026, closing a stake of 28,602 shares — an estimated $40K sold.

Creative Planning first reported a position in MAIA in Q4 2025 and held it in 2 quarters. The position peaked at $44.1K in Q4 2025. 36 funds tracked by Wall St. Rank hold MAIA as of Q2 2026.

  • Creative Planning reported no remaining MAIA Biotechnology position as of Q2 2026 after selling out during the quarter.
  • Creative Planning sold 28,602 MAIA Biotechnology shares in Q2 2026, an estimated $40K.
  • Creative Planning first reported a position in MAIA Biotechnology in Q4 2025 and held it in 2 quarters.
  • Creative Planning's MAIA Biotechnology position peaked at $44.1K in Q4 2025.
  • 36 funds tracked by Wall St. Rank held MAIA Biotechnology as of Q2 2026.

Based on Creative Planning's 13F filing for Q2 2026, filed 13 Aug 2026.